Skip to Content
Merck
All Photos(2)

Key Documents

H5270

Sigma-Aldrich

Hydrocortisone 17-butyrate

Synonym(s):

11β,17,21-Trihydroxypregn-4-ene-3,20-dione 17-butyrate, Cortisol 17-butyrate

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C25H36O6
CAS Number:
Molecular Weight:
432.55
EC Number:
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:

form

solid

Quality Level

shipped in

ambient

storage temp.

room temp

SMILES string

[H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])CC[C@]4(OC(=O)CCC)C(=O)CO

InChI

1S/C25H36O6/c1-4-5-21(30)31-25(20(29)14-26)11-9-18-17-7-6-15-12-16(27)8-10-23(15,2)22(17)19(28)13-24(18,25)3/h12,17-19,22,26,28H,4-11,13-14H2,1-3H3/t17-,18-,19-,22+,23-,24-,25-/m0/s1

InChI key

BMCQMVFGOVHVNG-TUFAYURCSA-N

Gene Information

human ... NR3C1(2908)

Looking for similar products? Visit Product Comparison Guide

Application

Hydrocortisone 17-butyrate may be used:
  • in the synthesis of hydrocortisone butyrate (HB)-loaded poly(d,l-lactic-co-glycolic acid) (PLGA) nanoparticles
  • as a topical corticosteroid (CS) to study its effects on keratinocyte proliferation in hyperproliferant keratinocytes (HaCaT) model
  • in the preparation of solid lipid nanoparticles (SLN)

Biochem/physiol Actions

Hydrocortisone 17-butyrate is a corticosteroid that acts as a dermocorticoid due to its application in dermatological therapy. It exhibits therapeutic effects against vitiligo of the face and neck.

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M Caproni et al.
Clinical and experimental dermatology, 31(6), 813-817 (2006-10-17)
Topical tacrolimus represents an effective and well-tolerated treatment for atopic dermatitis (AD). Its known effects include reduced production of proinflammatory cytokines and reduced chemokine gradient. We performed lesional skin biopsies on adult patients affected by moderate-to-severe AD. Then, patients were
Lawrence Eichenfield et al.
Pediatric dermatology, 24(1), 81-84 (2007-02-16)
Corticosteroids are currently the first line of treatment for patients with atopic dermatitis. In the pediatric population however, the potential impact of adrenal suppression is always an important safety concern. Twenty boys and girls, 5-12 years of age, with normal
S Reitamo et al.
The British journal of dermatology, 152(6), 1282-1289 (2005-06-14)
Atopic dermatis (AD) is a chronic disease that often requires long-term treatment. Topical corticosteroids are the usual therapy for patients with AD, but prolonged usage can result in skin atrophy and other side-effects. In a randomized, double-blind, comparative study, to
E Antiga et al.
Clinical and experimental dermatology, 36(3), 235-241 (2010-11-13)
Alterations of Toll-like receptors (TLRs) seem to play a role in susceptibility to atopic dermatitis (AD). To investigate the expression of TLRs in moderate to severe chronic AD in adults before and after a 3-week treatment with 0.1% tacrolimus ointment
P Mercy et al.
Indian journal of dermatology, venereology and leprology, 73(6), 415-416 (2007-11-23)
Acquired Blaschkoid dermatitis characterised by unilateral relapsing inflammatory disease along the lines of Blaschko. A 40-year-old Indian male presented with unilateral erythematous, itchy grouped papules on the left side of the chest, abdomen, back and left arm of 15 days

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service